Whose Genetics Are We Testing? Dr. Kenn Chi Ndi Highlights Cancer Genomics Gaps at SCHD26

Cancer genomics research has long overlooked African populations, creating major gaps in precision oncology. At SCHD26, Dr. Kenn Chi Ndi presented important findings on BRCA1 and BRCA2 mutations in Cameroonian breast cancer patients, underscoring the need for culturally appropriate genetic counseling, more inclusive research, and equitable access to cancer prevention and treatment strategies.

Why SCHD26 Spotlighted This Research

The Summit on Cancer Health Disparities (SCHD26) saw its biggest attendance to date and garnered a record-breaking number of abstract submissions. This meant that the disparities-focused conversation within the collaborative research space was sharper and more informed than ever—and the calls to action that stemmed from it achieved the widest possible reach. In this vein, SCHD26 provided a platform for first authors of top submitted abstracts to share their research.

Key takeaways

• Dr. Kenn Chi Ndi presented research at SCHD26 on BRCA1 and BRCA2 mutations in Cameroonian breast cancer patients.
• The study highlighted how African populations remain severely underrepresented in cancer genomics research.
• Findings suggest that higher-risk populations may be receiving less attention in precision oncology research and care.
• The research incorporated culturally sensitive pre-test genetic counseling rather than a one-size-fits-all model.
• The study helps lay groundwork for more equitable cancer prevention, genetic testing, and precision medicine access in vulnerable populations.

Dr. Kenn Chi Ndi Presented a Study on BRCA Mutations in Cameroonian Patients

Dr. Kenn Chi Ndi, from the Centre Hospitalier Regional d'Ebolowa in Cameroon, presented his abstract “Characterizing BRCA1 and BRCA2 mutations in Cameroonian breast cancer patients: Efforts towards bridging the genomic gap in Africa.” The abstract was co-authored by Dr. Berthe Sabine Esson Mapoko, Dr. Vanessa Mouaye, Dr. Bonaventure Dzekem, Dr. Paul Ndom, Dr. Dezheng Huo, and Dr. Olufunmilayo Olopade.

As the group’s abstract states plainly, “There are profound global inequities in cancer genomics research, with publications focusing on cancer genetics from Africa representing only 0.016% of the global total.” The targeted therapies that fall under the umbrella of precision oncology, then, aren’t taking into account the genetics of an entire continent. Dr. Ndi’s “pioneering study” provided genetic testing for a group of 82 cancer patients based in Cameroon. They found that the gene mutation that significantly increases risk of breast and other cancers was more frequent in their samples than in better-studied populations—meaning the more at-risk population was receiving the least attention.

Why Africa’s Genomic Gap Matters in Precision Oncology

The researchers did not pursue the one-size-fits-all approach that had left the Cameroonian patients behind in the first place. They employed “culturally sensitive pre-test genetic counseling” before collecting their sample.

Ultimately, Dr. Ndi’s research, given a global stage at SCHD26, addresses a critical knowledge gap.

“Our work provides a foundation for developing culturally-appropriate cancer prevention strategies,” Dr. Ndi’s abstract concludes, “reducing genetic testing disparities, and advancing precision medicine accessibility in vulnerable populations, ultimately contributing to the global effort to eliminate cancer health disparities.”

Frequently Asked Questions About Cancer Genomics Disparities and BRCA Research

What did Dr. Kenn Chi Ndi present at SCHD26?

Dr. Kenn Chi Ndi presented research on BRCA1 and BRCA2 mutations in Cameroonian breast cancer patients, focusing on disparities in cancer genomics research and access to precision oncology.

Why is this study important?

The study addresses a major knowledge gap in global cancer genomics by examining an underrepresented population that is often excluded from genetic research and targeted treatment development.

What makes this research relevant to cancer health disparities?

It shows how unequal representation in genomics research can limit prevention, diagnosis, and treatment options for vulnerable populations, especially in Africa.

How did the researchers approach patient care differently?

They used culturally sensitive pre-test genetic counseling, recognizing that genetic testing must be adapted to the community and patient context rather than relying on a one-size-fits-all approach.

How does this research support precision medicine?

The findings help build a foundation for more inclusive genetic databases, better risk assessment, and more equitable access to targeted cancer care.